William Blair analyst Brandon Vazquez has maintained their bullish stance on ELAN stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Brandon Vazquez has given his Buy rating due to a combination of factors that highlight Elanco Animal Health’s potential for sustainable growth. One of the primary reasons is the company’s strategic focus on its dual channel pet health strategy, which involves both retail and prescription channels. This approach is aimed at addressing the diverse needs of customers by providing more convenient and valuable access to medications, especially as the retail segment has now stabilized and is seen as essential for meeting growing demand.
Additionally, Elanco’s robust innovation pipeline is a significant factor in Vazquez’s positive outlook. The company has outlined over 15 projects in critical areas such as parasiticides, dermatology, pain management, and chronic kidney disease, with several projects expected to become blockbuster products. These initiatives are anticipated to drive three waves of innovation over the next decade, potentially exceeding Elanco’s long-term financial targets. With the stock trading at 21 times the estimated earnings per share for 2026, Vazquez sees substantial upside potential, reinforcing his Buy recommendation.
According to TipRanks, Vazquez is a 3-star analyst with an average return of 3.4% and a 46.67% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Ceribell, Inc., Penumbra, and Zoetis.
In another report released today, KeyBanc also maintained a Buy rating on the stock with a $27.00 price target.